Hot Features
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Pha... Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0185 | -7.11538461538 | 0.26 | 0.26 | 0.236 | 1427788 | 0.24549954 | DE |
| 4 | -0.1485 | -38.0769230769 | 0.39 | 0.4435 | 0.236 | 2456243 | 0.31264312 | DE |
| 12 | -0.1855 | -43.4426229508 | 0.427 | 0.465 | 0.236 | 2104867 | 0.36559494 | DE |
| 26 | -0.0655 | -21.335504886 | 0.307 | 0.808 | 0.236 | 2967810 | 0.41398705 | DE |
| 52 | -0.1045 | -30.2023121387 | 0.346 | 0.808 | 0.236 | 1724179 | 0.40240495 | DE |
| 156 | -0.0545 | -18.4121621622 | 0.296 | 1.04 | 0.1544 | 627241 | 0.41513507 | DE |
| 260 | -1.6085 | -86.9459459459 | 1.85 | 2.29 | 0.1544 | 397487 | 0.4560918 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.